Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer

Interim Analysis of Phase 2 Clinical Data Published at the American Society of Clinical Oncology 43rd Annual Meeting

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation today released interim findings from its Phase II, multi-center clinical study of Amrubicin, the company's third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. These findings indicate favorable interim results in terms of response rate and safety when comparing Amrubicin to the current treatment standard, topotecan, in second-line treatment of platinum-sensitive small-cell lung cancer patients with extensive disease (ED-SCLC). The early results of this study were published online on the ASCO website during the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. (June 1- 5, 2007).

"Oncologists have very limited treatment options available for patients with extensive-disease small cell lung cancer, and regrettably, patients with this disease still have an exceptionally poor prognosis," said Andrew R. Allen, chief medical officer of Pharmion. "We are encouraged by these initial results which suggest Amrubicin's potential to improve the treatment landscape for small cell lung cancer."

The trial compares Amrubicin and topotecan in patients with ED-SCLC that initially responded to first-line platinum-based therapy but recurred or progressed at least 90 days after completion of first-line treatment. Study participants are randomized 2:1 to receive either Amrubicin (40 mg/m2 via 5- min.infusion daily x 3 days) or topotecan (1.5 mg/m2 via 30-min. infusion daily x 5 days), both starting on Day 1 of a 21-day cycle.

Response data from 24 evaluable patients have been analyzed, 15 treated with Amrubicin and nine with topotecan. Of the 15 Amrubicin patients, 40 percent showed an objective tumor response, including two complete r
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:5/23/2013)... , May 23, 2013  BioElectronics Corporation (OTC Pink: ... devices, comments on the FDA panel meeting for non-thermal ... Reclassification – Pulsed Shortwave Therapy Meeting was held on ... , USA.  The focus of the meeting was very ... to focus solely on the application of non-thermal shortwave ...
(Date:5/23/2013)... Conn. , May 23, 2013  CAS Medical Systems, ... medical devices for non-invasive patient monitoring, today announced that ... Officer,  will present at the 2 nd Annual Marcum ... Hyatt Hotel in New York City . ... p.m. ET in the Estate 10 room and will be ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 /PRNewswire/ ... ) today announced the appointment of ... Officer.  Mr. Ramsay was most recently Vice President, ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO )     "With his established ... operational experience gained by working in our commercial ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
... 14 The Clinical Trials,Bootcamp announces its inaugural ... staff and other participants in,clinical trial. It will ... Resort from May,14-17th, 2009. Physician investigators, clinical coordinators, ... how to incorporate,clinical trials into a practice, as ...
... in late 2008 or in early 2009 -, ... NUVO ) today announced positive results from the Phase ... rapidly produced and maintained anticoagulation with a rapid,return toward ... "NU172 has the potential to address many of ...
Cached Medicine Technology:Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4
(Date:5/24/2013)... 24, 2013 According to the National Institutes ... toxic epidermal necrolysis (TEN) that affects the skin and mucous ... adults under the age of 30 (i). In the ... and fever. As SJS advances, it affects the mucous ... and anus. Inflammation of the eye causes conjunctivitis (pink ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- The number ... units after spending time in an emergency room ... new research. The study, conducted by researchers ... Health and Health Services in Washington, D.C., found ... room on average before being admitted to the ...
(Date:5/24/2013)... new investigational device - the Helio System (TF-FA) - ... Heart Valve was successfully deployed in all four patients ... in high-risk aortic insufficiency reported at EuroPCR 2013. , ... help stabilise the SAPIEN XT valve for patients with ... captured between the transcatheter heart valve and the dock. ...
(Date:5/24/2013)... May 24, 2013 The producers of ... dates for Charlotte, North Carolina. It is one of the ... 500 companies. The city is populated with more than a ... cover residents in both North and South Carolina. Viewers who ... medically-related can tune into WAXN-TV 64 Eyewitness News during the ...
(Date:5/24/2013)... NY (PRWEB) May 24, 2013 The ... is happy to announce that it has donated $10,000 to ... the women held captive in Cleveland, Ohio. , “When the ... Jesus, Michelle Knight, and Amanda Berry and her daughter had ... a decade, we were shocked and horrified,” said Integrative Nutrition ...
Breaking Medicine News(10 mins):Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Feasibility trial reports deployment of new device for TAVI in aortic insufficiency 2Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2Health News:Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund 2
... April 23 (HealthDay News) -- It goes without saying that ... they can also be very expensive, an expert warns. ... a person bitten by a venomous snake, said Jill Heatley, ... in College Station. The total cost includes hospitalization, which ...
... The International and American Associations for Dental ... in children. These articles, titled "Hypoplasia-Associated Severe Early ... Page Caufield, New York University College of Dentistry) ... (lead author M.E.C. Elfrink, Academic Centre for Dentistry, ...
... destruction of the insulin-producing beta cells. Over 250,000 patients suffer ... daily insulin injections to maintain glucose metabolism. Replacement of the ... organ or isolated human beta cells is the only effective ... of organ donors this method can be offered to only ...
... St. Jude Children,s Research Hospital scientists have rewritten the ... it guards early brain cells from DNA damage. Such ... showed that cells in the developing brain require TopBP1 ... is copied prior to cell division. Investigators also reported ...
... That "brain freeze" headache you experience when eating ice cream ... change in brain blood flow, researchers report. What,s more, ... more troubling forms of headache such as migraine, the U.S. ... blood flow in 13 healthy adults as they sipped ice ...
... April 22 (HealthDay News) -- Tick season has started earlier ... gardeners and others who love the outdoors should take precautions ... People also should keep alert for symptoms of tick-borne ... tick-borne diseases such as Lyme disease, anaplasmosis and babesiosis -- ...
Cached Medicine News:Health News:Cost of Snakebite Therapy May Squeeze Victims' Wallets 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 3Health News:Xenotransplantation as a therapy for type 1 diabetes 2Health News:Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor 2Health News:Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor 3Health News:'Ice Cream Headaches' Might Offer Clues to Migraines 2Health News:Tick Season Starting Early This Year 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: